The Valley Desk

ArticleFrontiers in oncologyPublished

Time and cost burden associated with docetaxel in patients with metastatic castration-sensitive prostate cancer initiating an androgen receptor pathway inhibitor-based regimen

Read the publication ↗ Open access copy ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

Publication record

Type
Article
Venue
Frontiers in oncology
Published
Subject terms
Prostate neoplasms; Chemotherapy; Androgen Receptor Antagonists; Triplet Therapy; Time Burden; Mcspc; Hormone Receptor Agonists
PubMed ID
41079090
PubMed Central ID
PMC12512215
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal